Relative Effectiveness of the MF59-Adjuvanted Influenza Vaccine Versus High-Dose Influenza Vaccine in Older Adults With Influenza Risk Factors During the 2019–2020 US Influenza Season
Open Forum Infectious Diseases · 30.07.2024 · 11 (8)
DOI: 10.1093/ofid/ofae459 ↗Kurz gefasst
Fachartikel in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 16.08.2024. Verfasst von Mahrukh Imran und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center for Outcomes Research & Epidemiology, CSL Seqirus, Kirkland, Quebec, Canada. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CSL Seqirus.
Themen: Gerontologische Pflege
Abstract (Originalsprache)
Background
This study estimated the relative vaccine effectiveness (rVE) of the MF59-adjuvanted trivalent influenza vaccine (aTIV) versus high-dose trivalent inactivated influenza vaccine (HD-TIV) for prevention of influenza-related medical encounters (IRMEs) during the 2019–2020 United States (US) influenza season stratified by the cumulative number of influenza risk factors. A secondary objective evaluated outpatient IRMEs and influenza- and pneumonia-related hospitalizations.
Methods
This retrospective cohort study included US adults ≥65 years old vaccinated with aTIV or HD-TIV between 1 August 2019 and 31 January 2020. Electronic health records linked to claims were used to ascertain exposure, covariates, risk factors, and outcomes. Multivariable adjusted odds ratios (ORs) were derived using inverse probability of treatment–weighted samples to calculate rVEs independently for individuals with 0, ≥1, 1–2, or ≥3 risk factors.
Results
The study included 1 115 725 aTIV and 2 561 718 HD-TIV recipients. For the primary outcome of any IRME, the analysis found comparable effectiveness between aTIV and HD-TIV (rVE, 5.2% [95% confidence interval {CI}, −5.9% to 15.1%]) among those with 0 risk factors, whereas aTIV was more effective than HD-TIV among patients with ≥1, 1–2, or ≥3 risk factors (12.5% [95% CI, 10.0%–15.0%], 18.4% [95% CI, 13.7%–22.9%], and 10.4% [7.4%–13.3%], respectively). The same trends were observed for the secondary outcomes.
Conclusions
This study demonstrated comparable effectiveness of aTIV and HD-TIV among individuals with no identified risk factors and higher effectiveness of aTIV compared with HD-TIV in preventing any IRMEs, outpatient IRMEs, and influenza- or pneumonia-related hospitalizations among those with at least 1 or multiple high-risk factors in adults ≥65 years old.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Outcomes Research & Epidemiology, CSL Seqirus, Kirkland, Quebec, Canada.
- Real World Evidence, Veradigm, Chicago, Illinois, USA.
- Center for Outcomes Research & Epidemiology, CSL Seqirus, Waltham, Massachusetts, USA.
- Center for Outcomes Research & Epidemiology, CSL Seqirus, Amsterdam, The Netherlands.
ORCID-Profile: Mahrukh Imran, Ian McGovern
Förderung
- CSL Seqirus
Zitieren
APA
Imran, M., Mills, C. W., McDermott, K. W., Dean, A., Bogdanov, A., McGovern, I., & Haag, M. D. M. (2024). Relative Effectiveness of the MF59-Adjuvanted Influenza Vaccine Versus High-Dose Influenza Vaccine in Older Adults With Influenza Risk Factors During the 2019–2020 US Influenza Season. Open Forum Infectious Diseases, 11(8). https://doi.org/10.1093/ofid/ofae459
Vancouver
Imran M, Mills CW, McDermott KW, Dean A, Bogdanov A, McGovern I, et al. Relative Effectiveness of the MF59-Adjuvanted Influenza Vaccine Versus High-Dose Influenza Vaccine in Older Adults With Influenza Risk Factors During the 2019–2020 US Influenza Season. Open Forum Infectious Diseases. 2024;11(8). doi:10.1093/ofid/ofae459
BibTeX
@article{Imran2024,
author = {Imran, Mahrukh and Mills, Carrie W and McDermott, Kimberly W and Dean, Alex and Bogdanov, Alina and McGovern, Ian and Haag, Mendel D M},
title = {Relative Effectiveness of the MF59-Adjuvanted Influenza Vaccine Versus High-Dose Influenza Vaccine in Older Adults With Influenza Risk Factors During the 2019–2020 US Influenza Season},
journal = {Open Forum Infectious Diseases},
year = {2024},
volume = {11},
number = {8},
doi = {10.1093/ofid/ofae459}
}
EUVIMED